Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of an Automatic Closed-loop Insulin Delivery System

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02366767
Recruitment Status : Completed
First Posted : February 19, 2015
Results First Posted : February 6, 2017
Last Update Posted : March 17, 2017
Sponsor:
Collaborator:
Medtronic
Information provided by (Responsible Party):
Bruce A. Buckingham, Stanford University

Brief Summary:
The overall aim of this research proposal is to determine the safety, feasibility and efficacy of an automatic closed-loop insulin delivery system.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Device: Automatic closed-loop insulin delivery Device: Control Not Applicable

Detailed Description:

This study will be completed in two parts.

The initial part of this study will be an inpatient evaluation of the system with the primary goal of assessing safety and feasibility. This will involve 8 subjects with type 1 diabetes, aged 14 - 40 years, admitted for up to 60 hour. Plasma glucose levels will be collected hourly and tested by YSI (YSI 2300, Yellow Springs Instrument). These studies will be performed at Stanford University and will include group sporting activities to mimic the diabetes camp environment. Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise, and prebed by subjects with research staff supervision during the day and at 00:00, 03:00 and 07:00 by research staff. These data will be reviewed by the DSMB before proceeding to camp studies.

The second part of this study will be to test the efficacy of the system during diabetes summer camps. We will test the system in subjects with type 1 diabetes, aged 14-40 years, attending diabetes camp. There will be 20 subjects recruited, with 10 subjects randomized to the control arm Medtronic 530G system with threshold suspend (control group) and 10 subjects randomized to the automatic closed-loop insulin delivery (intervention group). Capillary blood glucose testing will be performed every 2-3 hours before meals, snacks, exercise and prebed by subjects with research staff supervision and at 00:00, 03:00 and 07:00 by research staff. The primary aim of this study is to generate preliminary data of system safety and efficacy in a closely supervised environment that challenges glucose control.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Assessment of an Automatic Closed-loop Insulin Delivery System
Study Start Date : June 2014
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: automatic closed-loop insulin delivery
The closed-loop arm will consist of participants wearing a sensor and transmitter which transmits sensor glucose data. The algorithm determines insulin delivery rates and this is delivered in microboluses every 5 minutes
Device: Automatic closed-loop insulin delivery
Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.

Active Comparator: Control
The subjects in the control arm will wear the 530G system using Enlite and MiniLink transmitter and threshold suspend.
Device: Control
Threshold suspend
Other Name: 530G Pump




Primary Outcome Measures :
  1. Safety of Automatic Closed Loop Insulin Delivery System in Adolescents and Adults With Type 1 Diabetes [ Time Frame: 6 days ]
    1. As measured by the number of events of plasma glucose values ≤ 50 mg/dL OR frequency of system alerts preceding a plasma glucose value of ≤ 50 mg/dL in all subjects
    2. As measured by the number of events of system alerts of plasma glucose values >300 mg/dL lasting for more than one hour in all subjects.
    3. As measured by number of events of serum ketones >3 mmol/L in all subjects
    4. As measured by the number of events meeting the criteria for severe hypoglycemia, defined as hypoglycemic seizure, loss of consciousness or coma or an event requiring administration of glucagon or IV glucose in all subjects


Secondary Outcome Measures :
  1. Feasibility of Using the Automatic Closed Loop Delivery System in Adolescents and Adults With Type 1 Diabetes [ Time Frame: 6 days ]
    1. As measured by the system initiating and operating properly for at least 75% of the time for 75% of subjects.
    2. As measure by the completion of study enrollment procedures and education on system use within 2 hours for 75% of the subjects.

  2. Efficacy of Hybrid Closed-loop System in Comparison With Control [ Time Frame: 6 days ]
    As measured by overall mean sensor glucose percent time in range 70-180 mg/dL.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Clinical diagnosis of type 1 diabetes

    • The diagnosis of type 1 diabetes is based on the investigator's judgment
    • C peptide levels and antibody determinations are not required
  2. Daily insulin therapy for ≥ 12 months
  3. Insulin pump therapy for ≥ 3 months
  4. Age 14.0 - 40.0 years
  5. Subject comprehends written English
  6. Female subjects who are sexually active must be on acceptable method of contraception e.g. oral contraceptive pill, diaphragm, IUD
  7. Female subjects past menarche must have a negative urine pregnancy test
  8. Informed consent form is signed by the subject and/or parent and assent assigned by the subject if under 18 years of age
  9. For subjects under 18 years, both the subject and parent/guardian understand the study protocol and agree to comply with it. Both parents must sign if possible.

Exclusion Criteria:

  1. Subject has a medical disorder that in the judgment of the investigator will affect the wearing of the devices or the completion of any aspect of the protocol
  2. Diabetic ketoacidosis in the past month
  3. Hypoglycemic seizure or loss of consciousness or an event requiring glucagon or IV glucose in the past 3 months
  4. Subject has a respiratory condition such as asthma, treated with systemic or inhaled corticosteroids in the previous 6 months or cystic fibrosis
  5. Subject has a history of any cardiac or vascular disorder such as myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, arrhythmia or thromboembolic disease
  6. Subject has a history of liver or kidney disease (other than microalbuminuria)
  7. Subject has active Graves' disease
  8. Subjects with inadequately treated thyroid disease or celiac disease
  9. Subject has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
  10. Subject has a history of diagnosed medical eating disorder
  11. Subject has a history of known illicit drug abuse
  12. Subject has a history of known prescription drug abuse
  13. Subject has a history of current alcohol abuse
  14. Subject has a history of visual impairment which would not allow subject to participate
  15. Subject has an active skin condition that would affect sensor placement
  16. Subject has adhesive allergies
  17. Subjects requiring an intermediate or long-acting insulin (such as NPH, detemir or glargine)
  18. Subjects requiring other anti-diabetic medications other than insulin (oral or injectable)
  19. Current use of oral/inhaled glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
  20. Subject is currently on beta blocker medication
  21. Subject is currently participating in another investigational study (drug or device)
  22. Subject is deemed by the investigator to be unwilling or unable to follow the protocol
  23. Presence of a febrile illness within 24 hours of enrollment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02366767


Locations
Layout table for location information
United States, California
Camp Conrad-Chinnock
Angelus Oaks, California, United States, 92305
Packard El Camino Hospital
Mountain View, California, United States, 94040
Lucile Packard Children's Hospital
Palo Alto, California, United States, 94304
Sponsors and Collaborators
Stanford University
Medtronic
Investigators
Layout table for investigator information
Principal Investigator: Bruce Buckingham, MD Stanford University

Publications of Results:
Layout table for additonal information
Responsible Party: Bruce A. Buckingham, MD, Stanford University
ClinicalTrials.gov Identifier: NCT02366767     History of Changes
Other Study ID Numbers: G140095
First Posted: February 19, 2015    Key Record Dates
Results First Posted: February 6, 2017
Last Update Posted: March 17, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Bruce A. Buckingham, Stanford University:
Insulin Infusion Systems
Continuous Glucose Monitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin
Insulin, Globin Zinc
Hypoglycemic Agents
Physiological Effects of Drugs